Stereotaxis, Inc.

Stereotaxis designs and sells robotic magnetic navigation systems used in minimally invasive cardiac and endovascular procedures. Its portfolio includes capital systems, disposable interventional devices, software, imaging and workflow tools, and service offerings sold primarily to hospitals and physicians in the United States, Europe, and other international markets.

−66,4 %

52,7 %

−66,8 %

+20,3 %

1.51

1.09

— Stereotaxis, Inc.
	%
Robotic magnetic navigation systems	35% Capital equipment used to remotely navigate catheters in electrophysiology and related procedures.
Disposable interventional devices	30% Single-use catheters and related devices used during ablation and other procedures.
Service and software	20% Maintenance plans, service-type warranties, and software enhancements for installed systems.
Diagnostic catheters	10% Map-iT branded diagnostic catheters acquired through APT and used in cardiac ablation procedures.
Royalties and other recurring revenue	5% Royalties and other recurring revenue from co-development, co-placement, and related arrangements.

Stereotaxis sells primarily to hospitals, electrophysiology labs, and physicians performing cardiac ablation and other...

Hospitals and electrophysiology labsprimary
Buy robotic magnetic navigation systems and related infrastructure for cardiac ablation programs.
Electrophysiologists and interventional physiciansprimary
Use disposable catheters, diagnostic devices, and software during procedures and drive clinical adoption.
International distributors and agentssecondary
Purchase or resell products in markets where the company uses indirect channels to expand reach.
Installed-base service customerssecondary
Buy maintenance plans, service-type warranties, and software updates for existing systems.

Stereotaxis markets its products in the U.S., Europe, and the rest of the world through direct sales and channel...

•United States is the core market and headquarters location
•Europe is a key market for robotic EP and catheter sales
•Rest of world sales are supported by distributors and agents
•APT catheter manufacturing is based in Rogers, Minnesota
•Geographic expansion depends on regulatory approvals and adoption

Stereotaxis is focused on expanding the installed base of robotic magnetic navigation systems and increasing...

Increase adoption of robotic magnetic navigation systemsshort-term

The installed base drives follow-on disposable, service, and software revenue.

Expand proprietary disposable device portfoliomedium-term

Recurring device sales improve procedure-level monetization and customer stickiness.

Broaden clinical applications beyond electrophysiologylong-term

New endovascular use cases can enlarge the addressable market for robotic navigation.

Strengthen in-house manufacturing and developmentmedium-term

Internal capability can improve control over product design, supply, and innovation.

The business depends on regulatory approvals, clinical adoption, and successful conversion of backlog into revenue, all...

high

Regulatory approval delays

New disposable devices and system features require clearance before commercialization.

Scope: Product pipeline and market expansion
Materiality: high

high

Clinical adoption risk

Hospitals and physicians may be slow to adopt robotic workflows or switch from conventional tools.

Scope: Installed base growth and utilization
Materiality: high

medium

Competitive pressure

The company competes with established device makers and robotic navigation developers.

Scope: Pricing, placement wins, and market share
Materiality: high

medium

Sales force and distributor execution

Revenue depends on access, training, and effective channel management across regions.

Scope: Commercial conversion and international expansion
Materiality: medium

medium

Acquisition integration

APT must be integrated into operations, quality systems, and product development plans.

Scope: Manufacturing, margins, and innovation
Materiality: medium

Revenue recognition by contract type

Reported revenue and gross margin can shift with product mix and billing terms

Deferred revenue and contract assets

Quarterly revenue and balance sheet working capital

Warranty and installation estimates

Cost of revenue and gross margin

Goodwill and intangible assets

Non-cash impairment charges if expected benefits do not materialize

Capitalized sales incentives

Operating expense timing and asset balances

Stereotaxis, Inc.

Regulatory approval delays

Clinical adoption risk

Competitive pressure

Sales force and distributor execution

Acquisition integration

Autonomix Medical, Inc.

Catheter Precision, Inc.

GLOBUS MEDICAL INC

Adagio Medical Holdings, Inc.

Neuraxis, INC

Neuronetics, Inc.